HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Cytokinetics (NASDAQ: CYTK) and maintained a price target of $140 for the stock.